Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Xilio Therapeutics (XLO) Accumulated Depreciation & Amortization (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Accumulated Depreciation & Amortization for 2 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 17.85% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, up 17.85% year-over-year, with the annual reading at $8.8 million for FY2025, 17.85% up from the prior year.
  • Accumulated Depreciation & Amortization hit $8.8 million in Q4 2025 for Xilio Therapeutics, up from $8.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.8 million in Q4 2025 to a low of $6.3 million in Q1 2024.